


The Burden of Alcohol Misuse

This presentation has been developed and fully funded
by Kyowa Kirin

Physical Impact of Alcohol Misuse

Chronic alcohol misuse is linked to more than 200 medical conditions ¹ including:

- Hypertension ¹
- Stroke ¹
- Pancreatitis ¹
- Liver Disease ¹
- Cancers (including mouth, head and neck, breast, bowel) ¹
- Sexually transmitted diseases ¹



Social Impact (England and Wales) of alcohol misuse

- Alcohol is thought to be a contributory factor in 13% of pedestrian road deaths ¹
- Alcohol misuse is a factor in 45% of suicides each year ²
- Alcohol plays a part in 25-33% of known cases of child abuse ²
- Each year in England more than 1.2 million violent incidents are linked to alcohol misuse ³
- More than 1 in 10 visits to accident and emergency (A&E) departments are because of alcohol-related illnesses ³



1. <https://alcoholeducationtrust.org/teacher-area/facts-figures/>

2. <https://www.gov.uk/government/publications/health-matters-harmful-drinking-and-alcohol-dependence/health-matters-harmful-drinking-and-alcohol-dependence>

3. <https://www.nhs.uk/conditions/alcohol-misuse/risks/>

Impact of alcohol misuse on Mental Health

- 19% of alcohol related hospital admissions are associated with mental and behavioural disorders ¹
- 86% of people accessing alcohol treatment services have a co-occurring mental health difficulty ¹
- An estimated 44% of community mental health patients reported problem drug use or harmful alcohol use in the previous year ¹

Prescribing Information

UK Prescribing information for Pabrinex® Intravenous High Potency (IVHP), Concentrate for Solution for Infusion

PABRINEX® Intravenous High Potency (IVHP), Concentrate for Solution for Infusion

Prescribing Information. Please refer to the full Summary of Product Characteristics before prescribing. **Name:** PABRINEX® Intravenous High Potency (IVHP), Concentrate for Solution for Infusion. **Active Ingredients:** Pabrinex IVHP is presented as a pair of (two) 5ml ampoules (labelled No. 1 and No. 2). Each No. 1 ampoule contains thiamine hydrochloride 250mg, riboflavin 4mg and pyridoxine hydrochloride 50mg. Each No. 2 ampoule contains ascorbic acid 500mg, nicotinamide 160mg and glucose (as monohydrate) 1000mg. **Indications:** Rapid therapy of severe depletion or malabsorption of the water-soluble vitamins B and C, particularly in alcoholism. **Dosage and Administration:** Before administration ensure both the Summary of Product Characteristics and ampoule labels refer to INTRAVENOUS infusion. **Adults:** The contents of 2 to 3 pairs of 5ml ampoules should be diluted with 50 to 100ml physiological saline or 5% glucose, and infused over 30 minutes every eight hours, or at the discretion of the physician. **Elderly:** As for adults. **Children:** Pabrinex IVHP is rarely indicated for administration to children; for further information refer to full SmPC. **Adverse Effects:** Hypersensitivity (including anaphylaxis, rash and urticaria), paraesthesia, hypotension, and injection site reactions. Prescribers should consult the summary of product characteristics for further details of side-effects. **Contraindications:** Known hypersensitivity to any of the active substances or excipients. **Precautions:** Potentially serious allergic reactions such as

anaphylactic shock may occur rarely, during or shortly after administration of Pabrinex IVHP. Symptoms such as sneezing or mild asthma are warning signs that further injections may give rise to anaphylactic shock. Facilities for treating anaphylactic reactions should be available whenever Pabrinex IVHP is administered. To minimise risk, infuse over 30 minutes. **Interactions:** The content of pyridoxine may interfere with the effects of concurrent levodopa therapy. **Pregnancy and Lactation:** No adverse effects have been noted during pregnancy or lactation at recommended doses when used as clinically indicated. The potential risk for humans is unknown. Caution should be exercised when prescribing to pregnant women. **Legal category:** POM. **Marketing Authorisation Holder:** Kyowa Kirin Limited, Galabank Business Park, Galashiels, TD1 1QH, UK. **Marketing Authorisation Number:** Pabrinex IVHP: PL 16508/0049. **NHS price:** Pabrinex IVHP as 6 pairs of 5 ml ampoules: £16.23; Pabrinex IVHP as 10 pairs of 5 ml ampoules: £22.53. **Date of prescribing information:** June 2018.

®Pabrinex is a registered trade mark.

Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse Events should also be reported to Kyowa Kirin Ltd. on +44 (0)1896 664000, email medinfo@kyowakirin.com



Prescribing Information

Republic of Ireland Prescribing information for Pabrinex® Intravenous High Potency (IVHP), Concentrate for Solution for Infusion

PABRINEX® Intravenous High Potency (IVHP), Concentrate for Solution for Infusion

Prescribing Information. Please refer to the full Summary of Product Characteristics before prescribing. **Name:** PABRINEX® Intravenous High Potency (IVHP), Concentrate for Solution for Infusion. **Active Ingredients:** Pabrinex IVHP is presented as a pair of (two) 5ml ampoules (labelled No. 1 and No. 2). Each No. 1 ampoule contains thiamine hydrochloride 250mg, riboflavin 4mg and pyridoxine hydrochloride 50mg. Each No. 2 ampoule contains ascorbic acid 500mg, nicotinamide 160mg and glucose (as monohydrate) 1000mg. **Indications:** Rapid therapy of severe depletion or malabsorption of the water-soluble vitamins B and C, particularly in alcoholism. **Dosage and Administration:** Before administration ensure both the Summary of Product Characteristics and ampoule labels refer to INTRAVENOUS infusion. **Adults:** The contents of 2 to 3 pairs of 5ml ampoules should be diluted with 50 to 100ml physiological saline or 5% glucose, and infused over 30 minutes every eight hours, or at the discretion of the physician. **Elderly:** As for adults. **Children:** Pabrinex IVHP is rarely indicated for administration to children; for further information refer to full SmPC. **Adverse Effects:** Hypersensitivity (including anaphylaxis, rash and urticaria), paraesthesia, hypotension, and injection site reactions. Prescribers should consult the summary of product characteristics for further details of side-effects. **Contraindications:** Known hypersensitivity to any of the active substances or excipients. **Precautions:** Potentially serious allergic reactions such as anaphylactic shock

may occur rarely, during or shortly after administration of Pabrinex IVHP. Symptoms such as sneezing or mild asthma are warning signs that further injections may give rise to anaphylactic shock. Facilities for treating anaphylactic reactions should be available whenever Pabrinex IVHP is administered. To minimise risk, infuse over 30 minutes. **Interactions:** The content of pyridoxine may interfere with the effects -of concurrent levodopa therapy. **Pregnancy and Lactation:** No adverse effects have been noted during pregnancy or lactation at recommended doses when used as clinically indicated. The potential risk for humans is unknown. Caution should be exercised when prescribing to pregnant women. **Legal category:** POM. **Marketing Authorisation Holder:** Kyowa Kirin Holdings B.V., Bloemlaan 2, 2132NP, Hoofddorp, Netherlands. **Marketing Authorisation Number:** Pabrinex IVHP: PA 2288/001/001. **Date of prescribing information:** November 2018.

®Pabrinex is a registered trade mark.

Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse Events should also be reported to Kyowa Kirin Ltd. on +44 (0)1896 664000, email medinfo@kyowakirin.com

